Active substances
Antazoline + Tetrahydrozoline
- SFDA 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| APILLERG EYE DROPS | 0.5,0.4 mg,mg | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 8.60 | Generic · OTC | Amman Pharmaceutical Industries (API) | Valid |
| OPTIZOLIN OPTHALMIC SOLUTION | 0.5,0.4 mg,mg | Ear drops, solution · Ophthalmic use | 1 Dropper Container | SAR 9.00 | Generic · OTC | Jamjoom Pharmaceuticals Factory Company | Valid |
| SPERSALLERG EYE DROPS | 0.5, 0.4 mg | Eye drops · Ocular use | 1 Dropper Container | SAR 11.65 | Generic · OTC | NOVARTIS | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ALLERGIC RHINITIS-ALLERGIC RHINO-CONJUNCTIVITIS; VIRAL CONJUNCTIVITS, HERPESVIRAL KERATITIS, HERPESVIRAL CONJUNCTIVITIS, VARICELLA KERATITIS, ZOSTER CONJUNCTIVITIS, ZOSTER KERATITIS, MEASLES KERATITIS AND KERATOCONJUNCTIVITIS, VIRAL CONJUNCTIVITIS, KERATITIS
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.